Business model

LiberoThera has obtained commercial licenses from RIKEN for the membrane protein technologies and has established the ground-breaking drug discovery platform allowing to generate distinctive therapeutic pipelines.

Structural GPCRs can be synthesized without mutations

(1) Therapeutic pipeline development

LiberoThera is developing novel therapeutics, such as antibody drugs targeting GPCRs, for treatment of cancer and some other chronical diseases.

(2) Technology alliance in collaborative discovery research

LiberoThera’s propriate drug discovery platform can be subjected for drug discovery research under collaboration.

LiberoThera's Business Model